Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

Ascendis Pharma (Nasdaq: ASND) commenced trading of its ordinary shares on the Nasdaq Global Select Market on April 20, 2026, replacing its American Depositary Shares (ADSs).

Rhea-AI Summary

Ascendis Pharma (Nasdaq: ASND) commenced trading of its ordinary shares on the Nasdaq Global Select Market on April 20, 2026, replacing its American Depositary Shares (ADSs).

The ordinary shares trade under the same ticker ASND, CUSIP K08588103 and ISIN DK0060606333. The company completed a mandatory exchange of all outstanding ADSs for ordinary shares, with the last ADS trading day on Nasdaq on April 17, 2026. A FAQ is available on the company investor website for details on the exchange and listing.

Positive

• Commenced trading on Nasdaq Global Select Market on April 20, 2026
• Completed 100% ADS exchange for ordinary shares as of April 20, 2026
• Ordinary shares retain ticker ASND and list under CUSIP/ISIN identifiers

Argus Apr 20 session

+0.37% close to close Open Argus

Details

News Market Reaction – ASND

On Apr 20, the day this news came out, ASND closed 0.37% above the previous close.

Data tracked by StockTitan Argus for the Apr 20 session.

Market Context

This announcement finalizes Ascendis’ transition from ADSs to directly listed ordinary shares on Nas...

Analysis

This announcement finalizes Ascendis’ transition from ADSs to directly listed ordinary shares on Nasdaq, with a 1-for-1 exchange effective April 20, 2026. It follows the earlier plan disclosed on April 8, 2026, which the market initially received positively. In recent months, the company also reported favorable clinical data and secured U.S. approval and orphan exclusivity for YUVIWEL through 2033. Investors may watch how the simplified structure affects liquidity, index eligibility, and access for different shareholder bases over time.

Key Figures

ADS exchange ratio: 1 ADS for 1 ordinary share ADS last trading day: April 17, 2026 Ordinary share trading start: April 20, 2026 +2 more

ADS exchange ratio

1 ADS for 1 ordinary share

Mandatory exchange of all outstanding ADSs

ADS last trading day

April 17, 2026

Final Nasdaq trading day for American Depositary Shares

Ordinary share trading start

April 20, 2026

Commencement of trading of ordinary shares on Nasdaq

CUSIP

K08588103

Identifier for Ascendis ordinary shares on Nasdaq

ISIN

DK0060606333

International identifier for Ascendis ordinary shares

Historical Context

5 past events · Latest: Apr 08

5 events

1. Apr 08

   Listing transition plan

   24h Move

   +5.8%

   Announced move from ADSs to direct Nasdaq listing of ordinary shares.

2. Apr 08

   Phase 2 COACH data

   24h Move

   +5.8%

   New Week 52 COACH trial data showing added benefits in achondroplasia.

3. Apr 06

   YUVIWEL exclusivity & launch

   24h Move

   -2.7%

   FDA orphan drug exclusivity and U.S. commercial launch of YUVIWEL.

4. Mar 17

   Turner syndrome trial data

   24h Move

   -1.3%

   New InsiGHTS Phase 2 data showing comparable efficacy to daily somatropin.

5. Mar 16

   ApproaCH 2-year data

   24h Move

   +2.0%

   Two-year ApproaCH data showing durable growth and proportionality benefits.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

american depositary shares, ads, nasdaq global select market, cusip, +1 more

5 terms

american depositary shares financial

"replacing the listing of American Depositary Shares (ADSs)."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

ads financial

"replacing the listing of American Depositary Shares (ADSs)."

Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.

nasdaq global select market financial

"its ordinary shares on The Nasdaq Global Select Market (Nasdaq)"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

cusip financial

"The ordinary shares trade under CUSIP number K08588103"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

isin financial

"and ISIN DK0060606333."

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq), replacing the listing of American Depositary Shares (ADSs).

The ordinary shares trade under the same ticker symbol “ASND” as previously used for the ADS listing. The ordinary shares trade under CUSIP number K08588103 and ISIN DK0060606333.

On April 8, 2026, the Company announced plans to mandatorily exchange all outstanding ADSs for ordinary shares, with each ADS exchangeable for one ordinary share listed on the Nasdaq. The last trading day for ADSs on Nasdaq was April 17, 2026. As of April 20, 2026, the Company has exchanged all outstanding ADSs for ordinary shares.

A list of frequently asked questions related to the listing of ordinary shares and exchange of ADSs is available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (ii) Ascendis’ ability to apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, and TransCon are trademarks owned by the Ascendis Pharma group. © April 2026 Ascendis Pharma A/S. 

Investor Contacts:	Media Contact:
Chad Fugere	Melinda Baker
Ascendis Pharma	Ascendis Pharma
+1 (650) 519-7494	+1 (650) 709-8875

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When did Ascendis Pharma (ASND) begin trading ordinary shares on Nasdaq?

Ascendis Pharma began ordinary-share trading on Nasdaq on April 20, 2026. According to the company, this replaced the prior ADS listing and followed the mandatory ADS exchange completed the same day.

What happened to Ascendis Pharma ADSs and when was the last ADS trading day for ASND?

All outstanding ADSs were mandatorily exchanged for ordinary shares; the last ADS trading day was April 17, 2026. According to the company, the exchange converted each ADS into one ordinary share listed on Nasdaq.

Does Ascendis Pharma keep the same ticker symbol after the listing change?

Yes, Ascendis Pharma continues to trade under the ticker ASND on Nasdaq. According to the company, the ordinary shares use the same symbol previously used for the ADS listing.

What identifiers apply to Ascendis Pharma ordinary shares on Nasdaq?

The ordinary shares trade under CUSIP K08588103 and ISIN DK0060606333. According to the company, these identifiers apply to the newly listed ordinary shares on Nasdaq Global Select Market.

How was the ADS-to-ordinary share conversion structured for ASND?

Each ADS was exchangeable for one ordinary share, resulting in a one-for-one mandatory exchange. According to the company, the exchange was completed and all outstanding ADSs were converted by April 20, 2026.

Where can investors find more details about the ASND listing and ADS exchange?

Investors can view a FAQ on the Ascendis Pharma investor website for guidance on the listing and exchange process. According to the company, the FAQ is posted in the Investors & News section of its website.